Analysis of the clinical effect of ambroxol hydrochloride on the treatment of COVID-19

doi:10.19871/j.cnki.xfcrbzz.2022.03.006

Abstract

Abstract: Objective To observe the clinical efficacy and safety of ambroxol hydrochloride on the treatment of Coronavirus disease 2019(COVID-19). Method A total of 68 patients with COVID-19 hospitalized in the Fifth Hospital of Shijiazhuang from January to June 2020 were selected and divided into control group and observation group, with 34 cases in each group. Both observation group and control group were given interferon-α5 million U, atomized, twice a day; arbidol 0.2g, orally, 3 times/d, for 10d. Observation group was treated with ambroxol hydrochloride glucose injection (30 mg, twice a day, iv drip) on the basis of conventional treatment for 2 weeks. The clinical efficacy, changes in serum inflammatory indexes and the incidence of adverse drug reactions were compared between the two groups. Result The total effective rate of observation group (85.3%) was significantly higher than that in the control group (70.6%) (P<0.05). The clinical symptoms improvement time, pulmonary imaging improvement time and hospitalization time in the observation group were shorter than those in the control group, but the differences were not statistically significant (P>0.05). The levels of serum PCT and CRP in the observation group were significantly lower after treatment than before (P<0.05), leukocyte count and lymphocyte count were significantly higher than those before treatment (P<0.05). In the control group the CRP level after treatment was significantly lower than that before treatment (P<0.05), the leukocyte count and lymphocyte count were significantly higher than those before treatment (P<0.05), but there was no significant difference in PCT level before and after treatment (P>0.05). There was no adverse reaction in the observation group and the control group during the treatment period. Conclusion Ambroxol hydrochloride treatment for COVID-19 patients can promote the remission of clinical symptoms and absorption of pulmonary lesions, and reduce inflammatory response, which is worthy of popularization and application.

Key words: Severe acute respiratory syndrome coronavirus 2, Pneumonia, Ambroxol, Clinical effect, C-reactive protein, Procalcitonin

Li Li, Zhang Xin, Dai Muwei, Zheng Huanwei, Kang Haiyan, Xu Yi, Hu Qian, Yang Li, Gao Huixia, Wang Yuling, Jiang Ping, Dai Erhei. Analysis of the clinical effect of ambroxol hydrochloride on the treatment of COVID-19[J]. Electronic Journal of Emerging Infectious Diseases, 2022, 7(3): 27-31.

References

[1] 中华人民共和国国家卫生健康委员会办公厅, 国家中医药管理局办公室.新型冠状病毒感染的肺炎诊疗方案(试行第五版)[EB/OL].[2020-02-20]. http://www.gov.cn/zhengce/zhengceku/2020-02/05/content_5474791.htm.
[2] ZHU N, ZHANG D, WANG W, et al.A novel coronavirus from patients with pneumonia in China, 2019[J]. N Engl J Med, 2020, 382(8):727-733.
[3] CHAN JFW, KOK KH, ZHU Z, et al.Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan[J]. Emerg Microbes Infect, 2020, 9(1): 221-236.
[4] GORBALENYA AE, BAKER SC, BARIC RS, et al.Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome-related coronavirus: classifying SARS-CoV-2 and naming it SARS-CoV-2[J]. Nat Microbiol, 2020, 5(4): 536-544.
[5] 中国疾病预防控制中心新型冠状病毒肺炎应急响应机制流行病学组. 新型冠状病毒肺炎流行病学特征分析[J] . 中华流行病学杂志, 2020,41(2): 145-151.
[6] PARUMS DV.EDITORIAL: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Patients[J]. Med Sci Monit, 2022, 28: e935952.
[7] 郭津含,陈建林,葛岚岚,等. 金银花对轻型新型冠状病毒肺炎治疗的药理价值[J/CD]. 新发传染病电子杂志, 2021, 6(3):181-188.
[8] HULL JD, LYON RA.In vitro pharmacology of ambroxol: Potential serotonergic sites of action[J]. Life Sci, 2018, 197: 67-72.
[9] 田卓民, 杜韵泽, 何慧英, 等. 沐舒坦治疗康复期 SARS 肺间质病变1例[J]. 临床肺科杂志, 2004, 9(5): 556-557.
[10] 李敏, 王进. 氨溴索治疗2019新型冠状病毒肺炎的研究现状[J]. 中国临床药理学杂志, 2020, 36(9): 1157-1159.
[11] MALERBA M, RAGNOLI B.Ambroxol in the 21st century: pharmacological and clinical update[J]. Expert Opin Drug Metab Toxicol, 2008, 4(8): 1119-1129.
[12] PALEARI D, ROSSI GA, NICOLINI G, et al.Ambroxol: a multifaceted molecule with additional therapeutic potentials in respiratory disorders of childhood[J]. Expert Opin Drug Discov, 2011, 6(11): 1203-1214.
[13] DEPFENHART M, VILLIERS D, LEMPERLE G, et al.Potential new treatment strategies for COVID-19: is there a role for bromhexine as add-on therapy?[J]. Intern Emerg Med, 2020, 15(5): 801-812.
[14] ALKOTAJI M.Azithromycin and ambroxol as potential pharmacotherapy for SARS-COV-2[J]. Int J Antimicrob Agents, 2020, 56(6):10619
[15] CARPINTEIRO A, GRIPP B, HOFFMANN M, et al.Inhibition of acid sphingomyelinase by ambroxol prevents SARS-CoV-2 entry into epithelial cells[J]. J Biol Chem, 2021, 296: 100701.
[16] 李菁, 朱凌云. 南京市79例普通型新型冠状病毒肺炎患者的用药情况分析及用药合理性评价[J]. 山东医药, 2020, 60(15):22-26.
[17] CHEN N, ZHOU M, DONG X, et al.Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study[J]. Lancet, 2020, 395(10223): 507-513
[18] XU Z, SHI L, WANG Y, et al.Pathological findings of COVID-19 associated with acute respiratory distress syndrome[J]. Lancet Respir Med, 2020, 8(4): 420-422.
[19] HUANG C, WANG Y, LI X, et al.Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet, 2020, 395(10223): 497-506.
[20] CHAN JFW, YUAN S, KOK KH, et al.A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster[J]. Lancet, 2020, 395(10223): 514-523.
[21] XU Z, SHI L, WANG Y, et al.Pathological findings of COVID-19 associated with acute respiratory distress syndrome[J]. Lancet Respir Med, 2020, 8(4):420-422.
[22] Tan L, Wang Q, Zhang D, et al.Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study[J]. Signal Transduct Target Ther, 2020, 5(1):33.
[23] 陈国华, 潘志伟, 白珺. 盐酸氨溴索对婴幼儿重症肺炎潮气呼吸肺功能的影响[J]. 泰山医学院学报, 2018, 39(3):324-325.
[24] 唐劲松, 宣春, 林景涛, 等. C-反应蛋白、白介素-6及降钙素原检测在新冠肺炎中的临床意义[J]. 实用医学杂志, 2020, 36(7):839-841.
[25] 郭蕊, 陈媛媛, 于智君, 等. 新型冠状病毒肺炎不同分型患者血清淋巴细胞计数、CRP、PCT、细胞因子水平变化及临床意义[J].海南医学, 2021, 32(24):3155-3158.